Charlotte, North Carolina (March 5, 2004) – BurnsAdler announced today that it has licensed three anti-epileptic products from Desitin Arzneimittel GmbH (“Desitin”) for promotion in Canada, Mexico and the Caribbean markets. The lead product is Apydan™ a twice daily oxcarbazepine tablet. In the United States the only oxcarbazepine on the market generated sales of over $200 million in 2003. According to IMS data, in Mexico sales of this same product were approximately $9 million or 6% of the $150 million Mexican anti-epileptic market.
